Feedback
Settings

Settings

Goto Application

1. WO2022098124 - NOVEL LACTOBACILLUS SP. STRAIN AND USE OF EXTRACELLULAR VESICLES DERIVED FROM SAME STRAIN

Submit observation
PermaLink
Publication Number WO/2022/098124
Publication Date 12.05.2022
International Application No. PCT/KR2021/015918
International Filing Date 04.11.2021
IPC
C12N 1/20 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
A61K 35/747
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
747Lactobacilli, e.g. L. acidophilus or L. brevis
A61P 29/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A61P 17/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C12R 1/225 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C-C12Q75
1Microorganisms
01Bacteria or actinomycetales
225Lactobacillus
Applicants
  • (주)프로스테믹스 PROSTEMICS CO. LTD. [KR]/[KR]
Inventors
  • 박병순 PARK, Byoung Soon
  • 최은욱 CHOI, Eun Wook
Agents
  • 황이남 HWANG, Enam
Priority Data
10-2020-014767306.11.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) NOVEL LACTOBACILLUS SP. STRAIN AND USE OF EXTRACELLULAR VESICLES DERIVED FROM SAME STRAIN
(FR) NOUVELLE SOUCHE DE LAUROBACILLUS SP. ET UTILISATION DE VÉSICULES EXTRACELLULAIRES DÉRIVÉES DE LA MÊME SOUCHE
(KO) 신규한 락토바실러스 속 균주 및 상기 균주 유래 세포외 소포의 용도
front page image
Abstract
(EN) The present invention relates to a novel Lactobacillus sp. strain and various uses of extracellular vesicles derived from the strain, and may provide novel Lactobacillus kefirgranum and extracellular vesicles derived therefrom. The present invention may also provide a pharmaceutical composition and antiviral composition for the prevention, amelioration or treatment of inflammatory diseases, comprising the extracellular vesicles as an active ingredient, and in particular, may provide a pharmaceutical composition which has fewer side effects than synthetic drugs and is effective in the prevention, amelioration or treatment of inflammatory bowel disease.
(FR) La présente invention concerne une nouvelle souche de Lactobacillus sp. et diverses utilisations de vésicules extracellulaires dérivées de la souche, et peut fournir un nouveau Lactobacillus kefirgranum et des vésicules extracellulaires dérivées de celui-ci. La présente invention peut également fournir une composition pharmaceutique et une composition antivirale pour la prévention, l'amélioration ou le traitement des maladies inflammatoires, comprenant les vésicules extracellulaires comme principe actif, et en particulier, peut fournir une composition pharmaceutique présentant moins d'effets secondaires que les médicaments synthétiques et étant efficace dans la prévention, l'amélioration ou le traitement des maladies inflammatoires de l'intestin.
(KO) 본 발명은 신규한 락토바실러스 속 균주 및 상기 균주로부터 유래한 세포외 소포의 다양한 용도에 관한 것으로, 신규한 락토바실러스 케피르그라늄 및 이로부터 유래된 세포외 소포를 제공할 수 있다. 또한, 상기 세포외 소포를 유효성분으로 포함하는 염증 질환의 예방, 개선 또는 치료용 약학 조성물 및 항바이러스용 조성물을 제공할 수 있으며, 특히 합성의약품보다 부작용은 낮으면서 염증성 장질환의 예방, 개선 또는 치료에 효과적인 약학 조성물을 제공할 수 있다.
Latest bibliographic data on file with the International Bureau
# -